Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Troy joins Sidley Austin Brown & Wood

This article was originally published in The Gray Sheet

Executive Summary

Former FDA Chief Counsel Dan Troy accepts position in firm's Life Sciences Practice & Appellate Litigation Group. He will focus on administrative and constitutional law and litigation, especially for the pharmaceutical, medical device and biotechnology industries, according to a Jan. 6 release. Colleen Klasmeier, who served as special assistant to the chief counsel under Troy, also is joining Sidley's Life Sciences Practice. Gerald Masoudi, formerly with Kirkland & Ellis, replaced Troy at FDA in November (1"The Gray Sheet" Nov. 22, 2004, p. 4)...

You may also be interested in...



Troy Advances Case For Preemption; Verdict On Liability Reform Still Pending

Product liability reform measures likely will have to include an alternative compensation program for injured consumers, former FDA Chief Counsel Daniel Troy said Jan. 26

FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure

The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said

Biogen Value-Based Contract Links Patient-Reported Outcomes To MS Drug Reimbursement

Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.

UsernamePublicRestriction

Register

MT021426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel